株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗血栓薬/抗凝血薬:各種技術と世界の市場

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 254864
出版日 ページ情報 英文 156 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
抗血栓薬/抗凝血薬:各種技術と世界の市場 Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets
出版日: 2016年09月09日 ページ情報: 英文 156 Pages
概要

世界の抗血栓薬/抗凝血薬の市場は2016年から2021年にかけて7.6%のCAGR (年間複合成長率) で推移し、2016年の189億ドルから、2021年には273億ドルの規模に成長すると予測されています。

当レポートでは、抗血栓薬/抗凝血薬の各種技術および市場を調査し、産業における近年の発展動向、主要薬剤と売上予測、特許の状況、心血管疾患の分類・リスク因子・症状・併存疾患、抗凝血薬・抗血小板薬・トロンビン阻害剤の概要、主な製品、市場規模の推移と予測、地域別の動向、競合状況、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 産業概要

  • 主な発展
    • CVD予防のターゲットとされる凝固因子
    • ロンビン阻害剤の解毒剤の開発
  • 主要薬剤の売上予測
  • XARELTO (RIVAROXABAN)
    • ELIQUIS (APIXABAN)
    • PRADAXA (DABIGATRAN ETEXILATE MESYLATE)
    • LOVENOX (ENOXAPARIN)
    • PLAVIX (CLOPIDOGREL)
  • 特許分析
    • 譲受人別
  • 心血管疾患の流行
    • リスク因子・予防法
  • 心血管疾患の分類
    • 冠動脈心疾患
    • 急性心筋梗塞
  • 循環系
    • 血管の構造
    • 血流
  • 症状
    • 血栓
    • 塞栓
    • 血流の変更
    • 深部静脈血栓症・肺塞栓症
  • 止血 (凝固プロセス)
  • 血栓塞栓症の併存疾患
    • 急性冠症候群
    • 虚血性心疾患
    • 狭心症
    • 慢性虚血性心筋症
    • 心突然死
    • 心房細動
    • 脳血管疾患
    • ステント血栓症
  • 人口統計

第4章 抗凝血薬

  • 概要
  • 製品
    • 低分子量ヘパリン
  • 経口抗凝血薬 (ビタミンK拮抗薬)
  • 世界市場の予測
    • 地域別
  • 競合分析

第5章 抗血小板薬

  • 概要
  • 製品
    • 経口抗血小板薬
  • 世界市場の予測
    • 地域別
  • 競合分析

第6章 トロンビン阻害剤

  • 概要
  • 製品
    • 直接トロンビン阻害剤
    • 血栓溶解薬
    • 直接Xa因子阻害薬
  • 世界市場の予測
    • 地域別の市場シェア
    • 薬剤タイプ別市場
  • R&D
  • 世界の抗凝血薬/抗血栓薬市場の予測
    • 地域別
  • 競合分析

第7章 企業プロファイル

  • ABBOTT LABORATORIES
  • ARMETHEON INC.
  • ASTRAZENECA
  • BAXTER INTERNATIONAL
  • BAYER AG
  • BIOVASCULAR INC.
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB CO.
  • CSL BEHRING
  • 第一三共
  • ELI LILLY
  • EMISPHERE TECHNOLOGIES
  • F. HOFFMANN-LA ROCHE AG
  • GENENTECH
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON
  • LIGAND PHARMACEUTICALS INC.
  • THE MEDICINES CO.
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • MICROBIX BIOSYSTEMS INC.
  • NOVARTIS
  • 小野薬品工業
  • 大塚製薬
  • PFIZER INC.
  • PORTOLA PHARMACEUTICALS
  • REVO BIOLOGICS INC.
  • SANOFI
  • SANTA CRUZ BIOTECHNOLOGY INC.
  • SERVIER LABORATORIES
  • SHIRE PHARMACEUTICALS
  • SUN PHARMACEUTICALS
  • TEVA PHARMACEUTICALS LTD.

第8章 付録A:特許リスト

第9章 付録B:企業ディレクトリー

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM119B

The global market for antithrombotic/anticoagulant drugs should reach $27.3 billion by 2021 from $18.9 billion in 2016 at a compound annual growth rate (CAGR) of 7.6%, from 2016 to 2021.

This report provides:

  • An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
  • Discussion of research and development of antithrombotic/anticoagulant treatments
  • Profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field

image1

REPORT SCOPE

SCOPE OF THE STUDY

This report is a comprehensive business tool designed to provide an in-depth look at antithrombotic/anticoagulant drugs for various cardiovascular applications. The geographic scope of the report is global, with a special emphasis on individual regions such as the United States, Europe, Asia-Pacific and the rest of world. The report describes the industry, its relationship to the healthcare industry and its participants and future trends.

Categories discussed in the report include:

  • Anticoagulants.
  • Antiplatelets.
  • Thrombin inhibitors.

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2016 to 2021 and assessing the competitors their market shares.

ANALYST'S CREDENTIALS

Anuj Pathak is a market research analyst and a management graduate in computer management. He has an MBA, BSc from Devi Ahilya University (Indore, India). Anuj has strong knowledge and expertise in the healthcare domain, and he has worked on a variety of projects in various domains, including healthcare and information and communication technology (ICT). He has conducted extensive research on the pharmaceutical market, the medical device market, the biotechnology market, the surgical instrument market and other niche markets. Anuj also has experience in leading and training research teams.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF THE STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • EXECUTIVE SUMMARY
  • SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)

CHAPTER 3 INDUSTRY OVERVIEW

  • MAJOR DEVELOPMENTS
    • COAGULATION FACTORS TARGETED TO REDUCE CVD
    • DEVELOPMENT OF ANTIDOTES FOR THROMBIN INHIBITORS
      • Andexanet Alfa
      • Praxbind (Idarucizumab)
      • TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL
  • SALES PERFORMANCE OF MAJOR DRUGS PROJECTED THROUGH 2020
  • XARELTO (RIVAROXABAN)
    • ELIQUIS (APIXABAN)
    • PRADAXA (DABIGATRAN ETEXILATE MESYLATE)
    • LOVENOX (ENOXAPARIN)
    • PLAVIX (CLOPIDOGREL)
    • TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • PATENT ANALYSIS
    • PATENT BY ASSIGNEE
    • FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
    • FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
  • EPIDEMIC OF CARDIOVASCULAR DISEASE
  • TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES
    • RISK FACTORS AND PREVENTION OF CVD
  • CLASSIFICATION OF CARDIOVASCULAR DISEASES
    • CORONARY HEART DISEASE
      • Prevalence of CHD in the U.S.
      • TABLE 4 CORONARY HEART DISEASE PROFILE
      • TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, 2013 (%)
    • ACUTE MYOCARDIAL INFARCTION
    • TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE
  • THE CIRCULATORY SYSTEM
    • BLOOD VESSEL STRUCTURE
    • BLOOD FLOW
  • CONDITIONS
    • THROMBUS
    • EMBOLUS
    • ALTERATIONS IN VENOUS FLOW
    • DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
    • TABLE 7 VIRCHOW'S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM
  • HEMOSTASIS (THE CLOTTING PROCESS)
  • DISEASES ASSOCIATED WITH THROMBOEMBOLISM
    • ACUTE CORONARY SYNDROME
    • ISCHEMIC HEART DISEASE
      • Etiology
      • Mechanisms of Coronary Atherosclerosis
      • Pathophysiology of Ischemia
    • ANGINA PECTORIS
    • CHRONIC ISCHEMIC CARDIOMYOPATHY
    • SUDDEN CARDIAC DEATH
    • ATRIAL FIBRILLATION
      • Causes
    • CEREBROVASCULAR DISEASE
    • STENT THROMBOSIS
  • DEMOGRAPHICS
  • TABLE 8 GLOBAL POPULATION BY SELECTED REGION, 2000-2050 (MILLIONS)
  • TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH PER YEAR)
  • FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH)
    • CV, VTE, AF AND STROKE DEMOGRAPHICS
      • Venous Thromboembolism
        • Venous Thromboembolism and Lifestyle
        • Venous Thromboembolism and Air Travel

CHAPTER 4 ANTICOAGULANTS

  • OVERVIEW
  • PRODUCTS
    • LOW MOLECULAR WEIGHT HEPARIN
      • Lovenox
      • TABLE 10 LOVENOX DRUG LABEL
      • Fragmin
      • TABLE 11 FRAGMIN DRUG LABEL
      • Innohep
      • TABLE 12 INNOHEP DRUG LABEL
      • Orgaran
      • TABLE 13 ORGARAN DRUG LABEL
      • Normiflo
      • TABLE 14 NORMIFLO DRUG LABEL
      • Embolex
      • TABLE 15 EMBOLEX DRUG LABEL
      • Fraxiparine
      • TABLE 16 FRAXIPARINE DRUG LABEL
      • Ariven/Arteven
      • TABLE 17 ARIVEN/ARTEVEN DRUG LABEL
  • ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
  • GLOBAL MARKET FORECAST
  • TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
    • MARKET BY GEOGRAPHIC REGION
    • TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
    • FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
    • TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
    • FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
    • MARKET BY DRUG TYPE
    • TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, 2015-2021 ($ MILLIONS)
    • TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
    • FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
    • TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
    • FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • COMPETITIVE ANALYSIS
  • TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)

CHAPTER 5 ANTIPLATELETS

  • OVERVIEW
  • PRODUCTS
    • ORAL ANTIPLATELETS
      • Plavix
      • TABLE 27 PLAVIX DRUG LABEL
      • Pletal
      • TABLE 28 PLETAL DRUG LABEL
      • Effient
      • TABLE 29 EFFIENT DRUG LABEL
      • Ticlid
      • Brilinta
      • TABLE 30 BRILINTA DRUG LABEL
      • IV ANTIPLATELETS
      • Integrilin
      • TABLE 31 INTEGRILIN DRUG LABEL
      • Aggrastat
      • TABLE 32 AGGRASTAT DRUG LABEL
      • ReoPro
      • TABLE 33 REOPRO DRUG LABEL
  • GLOBAL MARKET FORECAST
  • TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, 2015-2021 ($ MILLIONS)
    • MARKET BY GEOGRAPHIC REGION
    • TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
    • FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
    • TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
    • FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
    • MARKET BY DRUG TYPE
    • TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
    • TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
    • FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
    • TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
    • FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
  • COMPETITIVE ANALYSIS
  • TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)

CHAPTER 6 THROMBIN INHIBITORS

  • OVERVIEW
  • PRODUCTS
    • DIRECT THROMBIN INHIBITORS
      • Argatroban
      • Angiomax
      • Iprivask
      • Pradaxa
    • THROMBOLYTIC AGENTS
      • Thrombolytic Enzymes
      • Tissue Plasminogen Activators
        • Activase
        • Retavase
        • TNKase
        • ATryn
    • DIRECT FACTOR XA INHIBITORS
      • Xarelto
        • Betrixaban
        • Savaysa (Edoxaban)
        • Eliquis
  • GLOBAL THROMBIN INHIBITOR MARKET FORECAST
  • TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, 2015-2021 ($ MILLIONS)
    • REGIONAL MARKET SHARES OF THROMBIN INHIBITORS
    • TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
    • FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
    • TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
    • FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
    • MARKET BY DRUG TYPE
    • TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, 2015-2021 ($ MILLIONS)
    • TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
    • FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
    • TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
    • FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
    • TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 ($ MILLIONS/%)
    • FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (%)
  • RESEARCH AND DEVELOPMENT
  • GLOBAL ANTICOAGULANT/ANTITHROMBOTIC MARKET FORECAST
  • TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
  • TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
    • MARKET BY GEOGRAPHIC REGION
    • TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
    • TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
    • FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
    • TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
    • FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
  • COMPETITIVE ANALYSIS
  • TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)

CHAPTER 7 COMPANY PROFILES

  • ABBOTT LABORATORIES
    • HISTORY
    • RECENT DEVELOPMENTS
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • ARMETHEON INC.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • CORPORATE MANAGEMENT
  • ASTRAZENECA
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • BAXTER INTERNATIONAL
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • BAYER AG
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • BIOVASCULAR INC.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • BOEHRINGER INGELHEIM GMBH
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • BRISTOL-MYERS SQUIBB CO.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • CSL BEHRING
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • DAIICHI SANKYO CO. LTD.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • ELI LILLY
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • EMISPHERE TECHNOLOGIES
    • HISTORY
    • PRODUCTS
    • CORPORATE MANAGEMENT
  • F. HOFFMANN-LA ROCHE AG
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • GENENTECH
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • GLAXOSMITHKLINE
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • JOHNSON & JOHNSON
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • LIGAND PHARMACEUTICALS INC.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • THE MEDICINES CO.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • CORPORATE MANAGEMENT
  • MERCK
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • MERRION PHARMACEUTICALS LTD.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • MICROBIX BIOSYSTEMS INC.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • NOVARTIS
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS:
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • ONO PHARMACEUTICAL CO. LTD.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • OTSUKA PHARMACEUTICAL CO. LTD.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • PFIZER INC.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS:
    • CORPORATE MANAGEMENT
  • PORTOLA PHARMACEUTICALS
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATION
    • CORPORATE MANAGEMENT
  • REVO BIOLOGICS INC.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • SANOFI
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • SANTA CRUZ BIOTECHNOLOGY INC.
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • SERVIER LABORATORIES
    • HISTORY
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • SHIRE PHARMACEUTICALS
    • HISTORY
    • PRODUCTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • SUN PHARMACEUTICALS
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT
  • TEVA PHARMACEUTICALS LTD.
    • HISTORY
    • PRODUCTS
    • RECENT DEVELOPMENTS
    • LOCATIONS
    • CORPORATE MANAGEMENT

CHAPTER 8 APPENDIX A: LIST OF PATENTS

  • TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL 2016

CHAPTER 9 APPENDIX B: DIRECTORY OF COMPANIES COVERED IN THIS REPORT

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL
  • TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES
  • TABLE 4 CORONARY HEART DISEASE PROFILE
  • TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, 2013 (%)
  • TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE
  • TABLE 7 VIRCHOW'S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM
  • TABLE 8 GLOBAL POPULATION BY SELECTED REGION, 2000-2050 (MILLIONS)
  • TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH PER YEAR)
  • TABLE 10 LOVENOX DRUG LABEL
  • TABLE 11 FRAGMIN DRUG LABEL
  • TABLE 12 INNOHEP DRUG LABEL
  • TABLE 13 ORGARAN DRUG LABEL
  • TABLE 14 NORMIFLO DRUG LABEL
  • TABLE 15 EMBOLEX DRUG LABEL
  • TABLE 16 FRAXIPARINE DRUG LABEL
  • TABLE 17 ARIVEN/ARTEVEN DRUG LABEL
  • TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
  • TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
  • TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • TABLE 27 PLAVIX DRUG LABEL
  • TABLE 28 PLETAL DRUG LABEL
  • TABLE 29 EFFIENT DRUG LABEL
  • TABLE 30 BRILINTA DRUG LABEL
  • TABLE 31 INTEGRILIN DRUG LABEL
  • TABLE 32 AGGRASTAT DRUG LABEL
  • TABLE 33 REOPRO DRUG LABEL
  • TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
  • TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
  • TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
  • TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
  • TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
  • TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
  • TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
  • TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
  • TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 ($ MILLIONS/%)
  • TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
  • TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
  • TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
  • TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL 2016

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
  • FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
  • FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH)
  • FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
  • FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
  • FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
  • FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
  • FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
  • FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
  • FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
  • FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
  • FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
  • FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
  • FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, 2015-2021 ($ MILLIONS)
  • FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
  • FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
  • FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (%)
  • FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
  • FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
  • FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
  • FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
  • FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
  • FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
  • FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
Back to Top